The Czech Academy of Sciences (the CAS) was established by Act No. 283/1992 Coll. as the Czech successor of the former Czechoslovak Academy of Sciences. It is set up as a complex of 54 public research institutions. The Academy employs over 8,000 employees more than a half of whom are researchers with university degrees.
The primary mission of the CAS and its institutes is to conduct basic research in a broad spectrum of the natural, technical and social sciences and the humanities. This research, whether highly specialised or interdisciplinary in nature, aims to advance developments in scientific knowledge at the international level, while also taking into account the specific needs of both Czech society and national culture. Scientists of the Academy institutes also participate in education, particularly through doctoral study programmes for young researchers and by teaching at universities as well. The Academy also fosters collaboration with applied research and industry. The integration of Czech science into the international context is being promoted by means of numerous joint international research projects and through the exchange of scientists with counterpart institutions abroad.
The supreme self-governing body of the Academy of Sciences is the Academy Assembly two-thirds of which is composed of representatives of all Academy institutes, the remaining third being representatives of universities, state administration, business circles, and other notable personalities. The executive body of the Academy is the Academy Council headed by the President of the Academy of Sciences. The Council for Sciences is primarily engaged in setting science policy of the Academy. Members of each of these Academy bodies are elected for a four-year-period. Academy Evaluation Committees, which correspond in their professional fields to respective science sections of the Academy, perform an independent assessment of the quality of research and research objectives of individual Academy institutes.
The Academy of Sciences is financed primarily from the state budget. The pattern of research funding at the Academy conforms to current international standards. In addition to basic institutional financing of research objectives of Academy institutes, target-oriented financing is being more widely practised to carry out research projects and grants selected on the basis of public competition. The CAS was the first institution in the Czech Republic to establish its own Grant Agency which financially supports research projects selected through a peer-review procedure involving reviewers from abroad. Individual Academy institutes obtain additional financial resources by participating in national as well as international research programmes.
The Academy has also been assigned financial responsibility for 71 specialised Czech scientific societies associated with the Council of Scientific Societies.
Contact
Address: Národní 3, 117 20 Praha 1, Czech Republic
Tel.: +420 221 403 111
E-mail: info@cas.cz
The president of the Czech Academy of Sciences highlights the responsibility of leading scientists to consider the real life application of their academic results in addition to promoting the Czech…
Against a backdrop of rising geopolitical tension, regulatory fragmentation, and mounting pressure on Europe’s healthcare systems, Prague-headquartered Zentiva is positioning itself as a distinctly European pharmaceutical player focused on long-term…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to attract customers across the country and beyond by positioning…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for download now. Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s…
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality of care across the country’s healthcare landscape, why greater levels of collaboration are of…
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical devices field, with their niche products addressing the unmet medical need in…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří Pavlíček, who combines the responsibility of Chairman of the association and CEO of the medtech…
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now multinational Czech CRO. Nevolová also shares her insights into the recent evolution of…
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning that it stands out as one of Central and Eastern Europe’s top destinations for clinical…
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working…
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is ahead of Pierre Fabre’s global transformation of the convergence between the dermo-cosmetic…
See our Cookie Privacy Policy Here
